Data of efficacy and toxicity for Radium-223 in patients with metastatic castration- resistant prostate cancer in real-life setting: A single-center experience

2018 ◽  
Vol 17 (14) ◽  
pp. e2851
Author(s):  
D. Akhoundova Sanoyan ◽  
D. Lorente Estelles ◽  
I. Burger ◽  
I. Engel ◽  
A. Mischo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Real Life ◽  
Castration Resistant Prostate Cancer ◽  
Single Center ◽  
Single Center Experience ◽  
Castration Resistant ◽  
Radium 223 ◽  
Real Life Setting

scholarly journals Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases

2020 ◽  
Vol 22 (4) ◽  
pp. 437
Author(s):  
Anil Kapoor ◽  
NathanC Wong ◽  
Yuding Wang ◽  
Som Mukherjee ◽  
Sebastien Hotte ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Castration Resistant Prostate Cancer ◽  
Single Center ◽  
Single Center Experience ◽  
Castration Resistant ◽  
Radium 223

scholarly journals Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of ‘real-life’ studies

2018 ◽  
Vol 10 (10) ◽  
pp. 305-315 ◽  
Author(s):  
Michele Marchioni ◽  
Petros Sountoulides ◽  
Maida Bada ◽  
Sebastiano Rapisarda ◽  
Cosimo De Nunzio ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Adverse Events ◽  
Meta Analysis ◽  
Real Life ◽  
Castration Resistant Prostate Cancer ◽  
The Real ◽  
Castration Resistant ◽  
Real Life Setting ◽  
Grade 3 ◽  
Baseline Psa

Background: To assess the efficacy and safety of treatment with abiraterone acetate (AA) in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) in the ‘real-life’ setting. Methods: Data acquisition on the outcomes of the use of AA in chemotherapy-naive patients with mCRPC was performed by a MEDLINE comprehensive systematic literature search using combinations of the following key words: ‘prostate cancer’, ‘metastatic’, ‘castration resistant’, ‘abiraterone’, ‘real life’, and excluding controlled clinical trials (phase II and III studies). Identification and selection of the studies was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) criteria. Outcomes of interest were overall survival (OS), progression-free survival (PFS), 12-week 50% reduction in prostate-specific antigen (PSA), and grade 3 and higher adverse events. Data were narratively synthesized in light of methodological and clinical heterogeneity. Results: Within the eight identified studies that fulfilled the criteria, a total of 801 patients were included in the meta-analysis. Baseline PSA ranged between 9.5 and 212.0 ng/ml. Most of the patients had bone metastases. Duration of treatment with AA was longer in the studies with lower baseline PSA levels. The median OS ranged between 14 and 36.4 months. The PFS, assessed according to different definitions, ranged from 3.9 to 18.5 months. A 50% PSA reduction at 12 weeks was reached by a variable percentage of patients ranging from 36.0% to 62.1%. Finally, the rate of grade 3 and higher adverse events was reported in three studies and ranged from 4.4% to 15.5%. Conclusions: Despite the high grade of heterogeneity among studies, treatment with AA seems to ensure good survival outcomes in the ‘real-life’ setting. However, prospective studies based on patients’ characteristics being more similar to ‘real-life’ patients are necessary.

scholarly journals Radium-223 in metastatic castration-resistant prostate cancer (mCRPC): efficacy and safety in real-life experience

2017 ◽  
Vol 28 ◽  
pp. vi23-vi24
Author(s):  
S.E. Rebuzzi ◽  
A. Prelaj ◽  
C. Pozzi ◽  
C. Ferrara ◽  
V. Frantellizzi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Life Experience ◽  
Real Life ◽  
Efficacy And Safety ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Radium 223

Survival outcome in patients with metastatic castration-resistant prostate cancer according to first-line treatment.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 5570-5570
Author(s):  
Marine Gross-Goupil ◽  
Nicolas H. Thurin ◽  
Magali Rouyer ◽  
Jérémy Jové ◽  
Thibaud Haaser ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Real Life ◽  
Abiraterone Acetate ◽  
Line Treatment ◽  
Castration Resistant Prostate Cancer ◽  
First Line ◽  
Free Survival ◽  
Castration Resistant ◽  
Real Life Setting ◽  
First Line Treatment

5570 Background: Therapeutic strategy in metastatic castration-resistant prostate cancer (mCRPC) has evolved significantly with the introduction of abiraterone acetate in association with prednisone/prednisolone in first-line treatment in December 2012. This work aimed to compare the effectiveness of abiraterone acetate and docetaxel as first-line treatments for mCRPC, in real-life setting. Methods: Patients with mCRPC were identified in the main scheme of the National Healthcare System database (SNDS), which covers about 86% of the French population, and capturing all reimbursed healthcare expenditures and hospital discharge summaries. Those initiating docetaxel or abiraterone acetate in 1st line in 2014 were included and 1:1 matched on the previous prostate cancer stage before mCRPC status, the delay from the date of initial diagnosis and a high-dimensional propensity score. The 36-month overall survival and the 36-month discontinuation-free survival (i.e. survival time until treatment switch or death) were compared using Cox proportional hazards risk model. Results: In 2014, out of the 12,951 patients with prevalent mCRPC, 1,214 initiated docetaxel in 1st line and 2 444 initiated abiraterone. A total of 716 patients per group were matched with good comparability (C-statistic = 0.6). The median duration of docetaxel–defined as the time between the first and the last infusion–was 7.3 months with a median of 6 infusions. The median duration of abiraterone acetate–corresponding to the period covered by the dispensed drug–was 9.1 months. Near 70% of the docetaxel and 62% of the abiraterone acetate patients received a 2nd line of treatment. Results related to the main survival outcomes are presented in the table below. Conclusions: First-line treatment with abiraterone acetate in mCRPC patients results in a better 36-month overall survival and discontinuation-free survival compared to docetaxel in real-life setting. [Table: see text]

scholarly journals Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience

2020 ◽  
Author(s):  
Yang Liu ◽  
Wen Long ◽  
Zitong Zhang ◽  
Lixin Mai ◽  
Sijuan Huang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Potential Benefit ◽  
Prognostic Index ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistance ◽  
Single Center ◽  
Single Center Experience ◽  
Castration Resistant ◽  
Significant Factors

Abstract Background: To investigate the potential benefit of cytoreductive radiotherapy (cRT) in metastatic castration-resistant prostate cancer (mCRPC) patients receiving abiraterone.Methods: From February 2014 to February 2019, 149 mCRPC patients treated with abiraterone were identified. Patients receiving cRT before abiraterone failure (AbiRT group) were matched by one-to-two propensity score to patients without cRT before abiraterone failure (non-AbiRT group).Results: The median follow-up was 23.5 months. Thirty patients (20.1%) were in the AbiRT group, whereas 119 patients (79.9%) were in the non-AbiRT group. The 2-year OS of patients managed by AbiRT and non-AbiRT were 89.5% and 73.5%, respectively (P = 0.0003). On multivariate analysis, only AbiRT (HR, 0.17; 95%CI, 0.05–0.58; P = 0.004) and prognostic index (HR 2.71; 95% CI, 1.37–5.35; P = 0.004) were significant factors. After matching, AbiRT continued to be associated with improved OS (median OS not reached vs. 44.0 months, P = 0.009). Subgroup analysis revealed that patients aged ≤65 years (HR, 0.09; 95%CI, 0.01–0.65; P = 0.018), PSA ≤20 ng/mL (HR 0.29; 95% CI, 0.09–0.99; P = 0.048), chemotherapy-naïve upon abiraterone treatment (HR 0.20; 95% CI, 0.06–0.66; P = 0.008) and in intermediate prognosis groups by COU-AA-301 prognostic index (HR 0.13; 95% CI, 0.03-0.57; P = 0.007) had improved OS with AbiRT. Conclusions: cRT before resistance to abiraterone may improve survival in selected mCRPC patients: age ≤65 years old, chemotherapy-naïve, with PSA ≤20 ng/mL at the diagnosis of mCRPC and intermediate prognosis.

Sign in / Sign up

Export Citation Format

Share Document